Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.

ABSTRACT:

Background

An essential criterion for control of acromegaly is normalization of IGF-I levels. Somatostatin analogues act to suppress IGF-I and GH levels.

Objective

To assess the efficacy and safety of 48 weeks titrated dosing of lanreotide Autogel.

Design

Open-label, multicentre, phase III, 48-week trial.

Methods

Patients with active acromegaly (IGF-I levels > 1.3 times upper limit of age-adjusted normal range) were recruited. Twelve injections of lanreotide Autogel were given at 28-day intervals: during the 16-week fixed-dose phase, patients received 90 mg; in the 32-week dose-titration phase, patients received 60, 90 or 120 mg according to GH and IGF-I levels. Intention-to-treat analysis was performed to determine the proportion of patients with normalized ag

SUBMITTER: Chanson P 

PROVIDER: S-EPMC2610402 | biostudies-literature | 2008 Aug

REPOSITORIES: biostudies-literature